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The loss of orexin neurons in humans is associated with the sleep disorder narcolepsy, which is characterized 
by excessive daytime sleepiness and cataplexy. Mice lacking orexin peptides, orexin neurons, or orexin recep-
tors recapitulate human narcolepsy phenotypes, further highlighting a critical role for orexin signaling in 
the maintenance of wakefulness. Despite the known role of orexin neurons in narcolepsy, the precise neural 
mechanisms downstream of these neurons remain unknown. We found that targeted restoration of orexin 
receptor expression in the dorsal raphe (DR) and in the locus coeruleus (LC) of mice lacking orexin receptors 
inhibited cataplexy-like episodes and pathological fragmentation of wakefulness (i.e., sleepiness), respectively. 
The suppression of cataplexy-like episodes correlated with the number of serotonergic neurons restored with 
orexin receptor expression in the DR, while the consolidation of fragmented wakefulness correlated with 
the number of noradrenergic neurons restored in the LC. Furthermore, pharmacogenetic activation of these 
neurons using designer receptor exclusively activated by designer drug (DREADD) technology ameliorated 
narcolepsy in mice lacking orexin neurons. These results suggest that DR serotonergic and LC noradrenergic 
neurons play differential roles in orexin neuron–dependent regulation of sleep/wakefulness and highlight a 
pharmacogenetic approach for the amelioration of narcolepsy.
Introduction
The neuropeptides orexin A and orexin B (also termed hypocretin-1 
and hypocretin-2, respectively) are implicated in feeding, the 
reward system, and sleep/wake regulation (1). They act on the 
G protein–coupled receptors orexin receptor type 1 (OX1R) 
and OX2R. Degenerative loss of orexin neurons in humans is 
associated with narcolepsy, a debilitating neurological disor-
der that provides a unique perspective on the mechanisms of 
sleep/wakefulness control (2). The syndrome consists of exces-
sive daytime sleepiness that often results in sleep attacks (sudden 
onset of non–rapid eye movement [NREM] sleep), cataplexy (sud-
den bilateral skeletal muscle weakening triggered by emotions, 
without consciousness impairment), hypnagogic hallucinations, 
and sleep paralysis.
The symptoms of narcolepsy can be divided into 2 independent 
pathological phenomena (1, 2). The first is dysregulation 
of NREM sleep onset: the inability to maintain a consoli-
dated awake period, characterized by abrupt transitions from 
wakefulness to NREM sleep. This phenomenon manifests clini-
cally as excessive daytime sleepiness or sleep attacks. The second 
is dysregulation of rapid eye movement (REM) sleep onset: the 
pathological intrusion of REM sleep or REM atonia into wake-
fulness or at sleep onset. It is during these periods that patients 
may experience cataplexy, hypnagogic hallucinations, and 
sleep paralysis.
Similarly, mice with targeted deletion of the prepro-orexin 
gene (orexin–/– mice), mice in which orexin neurons are specifi-
cally ablated (orexin/ataxin-3 mice), and mice that lack both orex-
in receptors (Ox1r–/–Ox2r–/– mice) display a phenotype strikingly 
similar to human narcolepsy, with markedly decreased duration 
of wakefulness episodes during the dark phase (i.e., inability 
to maintain a long awake period, or sleepiness), abrupt behav-
ioral arrests with muscle atonia (i.e., potentially cataplexy) that 
manifest as direct transitions from wakefulness to REM sleep 
in electroencephalogram/electromyogram (EEG/EMG) record-
ings, decreased REM sleep latency, and increased REM sleep time 
during the dark phase (1, 3–5).
Orexin neurons are distributed within the lateral hypothala-
mus and send projections throughout the brain and spinal 
cord, with particularly dense innervations to nuclei containing 
monoaminergic and cholinergic neurons that constitute the 
ascending activating system in the brainstem and the hypo-
thalamus. These include the noradrenergic neurons of the locus 
coeruleus (LC), the serotonergic neurons of the dorsal raphe 
nucleus (DR) and median raphe nucleus (MnR), the histamin-
ergic neurons of the tuberomammillary nucleus (TMN), and 
the cholinergic neurons of the laterodorsal tegmental nucleus 
(LDT) and pedunculopontine tegmental nucleus (PPT) (1). 
Application of orexin A directly into the LC (6), TMN (7), or 
LDT (8) has been reported to increase wakefulness. Further-
more, in vitro slice electrophysiology studies have shown that 
orexin A and orexin B increase the firing rates of monoaminer-
gic neurons in the LC (9, 10), DR (11, 12), and TMN (13–15) 
and cholinergic neurons in the LDT (16). These observations 
suggest that orexin neurons stabilize wakefulness by regulating 
these monoaminergic and cholinergic neurons (1).
However, neurons activated by pharmacological application of 
exogenous orexin may not necessarily be essential for the endog-
enous mechanisms by which orexin neurons regulate sleep/wake-
fulness in a physiological condition. In order to identify neurons 
that are directly activated by endogenous orexins and mediate 
their wake-stabilizing effect in a natural context, we searched for 
monoaminergic and cholinergic nuclei in which focal rescue of 
orexin receptor expression in Ox1r–/–Ox2r–/– mice ameliorated 
their narcoleptic phenotype.
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Results
Search for wake-active monoaminergic/cholinergic nuclei that mediate the 
suppression of narcoleptic symptoms by orexin neurons. Ox1r–/–Ox2r–/– 
mice display a phenotype that is strikingly similar to narcolepsy 
in the dark phase (1, 5): fragmented wakefulness (shorter dura-
tion and increased number of wakefulness episodes), cataplexy, 
shortened REM sleep latency, and excessive REM sleep time. In 
these mice, projections of orexin neurons to monoaminergic and 
cholinergic nuclei were retained to an extent similar to that in 
WT mice (Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI71017DS1). Thus, 
if the regional restoration of orexin receptors in a certain brain 
region suppresses narcoleptic symptoms in these mice, that par-
ticular region can at least be regarded as one of the important 
downstream targets of orexin neurons.
Sleep and wakefulness are controlled by a complex network of 
neurotransmitters and neuromodulators, including glutamate, 
GABA, monoamines, acetylcholine, and neuropeptides (1). As a 
first set of candidates in the search for the downstream targets 
of orexin neurons, we selected the serotonergic DR, noradrener-
gic LC, histaminergic TMN, and cholinergic PPT for 4 reasons: 
(a) these monoaminergic and cholinergic nuclei have long been 
implicated in sleep/wakefulness regulation, (b) they receive dense 
projections of orexin neurons, (c) good molecular markers are 
available to evaluate restoration efficiency, and (d) monoaminergic 
and cholinergic neurons of these nuclei are densely packed in rela-
tively small areas, which makes it comparatively easy to restore 
orexin receptors in most cells of a particular neuronal population 
using focal injection of recombinant viral vectors.
We generated recombinant adeno-associated viruses (AAVs) 
to express either OX1R or OX2R fused to EGFP under the con-
trol of the ubiquitous EF1α promoter (referred to herein as 
AAV-EF1α/OX1R::EGFP and AAV-EF1α/OX2R::EGFP). We then 
stereotaxically microinjected AAV-EF1α/OX1R::EGFP into the LC 
and PPT, or AAV-EF1α/OX2R::EGFP into the TMN and DR, of 
Ox1r–/–Ox2r–/– mice (bilaterally for LC, PPT, TMN; at midline for 
DR) and recorded EEG/EMG to score sleep/wakefulness states. 
The subtype of orexin receptors expressed was basically deter-
mined according to the expression of endogenous orexin receptors 
in WT mice (17, 18). Although the DR expresses both OX1R and 
OX2R, we assumed that restoration of either one would be suffi-
cient to recover orexin signaling in these cells, as both receptors are 
Gq-coupled and have caused strong excitatory effects on neurons 
examined thus far (1).
After completing EEG/EMG recordings, we evaluated the tar-
geted expression of orexin receptors in recorded mice in order 
to select those with restoration in more than approximately 
half of cells of interest before scoring the sleep/wake stages 
(Figure 1). In selected mice, a substantial proportion of nuclei-
specific monoaminergic or cholinergic neurons expressed 
OX1R::EGFP or OX2R::EGFP: 72.0% ± 3.2% of tryptophan 
hydroxylase–positive (TPH+) serotonergic neurons in the DR 
(n = 7), 83.2% ± 3.7% of tyrosine hydroxylase–positive (TH+) 
noradrenergic neurons in the LC (n = 8), 61.3% ± 5.0% of his-
tidine decarboxylase–positive (HDC+) histaminergic neu-
rons in the ventral TMN (n = 4), and 79.4% ± 2.9% of choline 
acetyltransferase–positive (ChAT+) cholinergic neurons in the PPT 
(n = 4). OX1R::EGFP or OX2R::EGFP expression was also 
observed in non-monoaminergic/non-cholinergic neurons with-
in and around the targeted nuclei (Figure 1).
We then analyzed the sleep/wakefulness patterns of selected 
Ox1r–/–Ox2r–/– mice with satisfactory restoration of orexin recep-
tor expression. As narcoleptic symptoms occur almost exclusively 
during the dark phase in mice, we hereafter describe sleep/wake-
fulness in this period. For cataplexy, we first confirmed in several 
mice that direct transitions from wakefulness to REM sleep in 
the EEG/EMG data perfectly correlated with episodes of abrupt 
immobility in the video data. Therefore, for the rest of the mice, 
we simply counted the direct transitions from wakefulness to REM 
sleep. We refer to these herein as cataplexy-like episodes, according to 
Scammell et al. (19) (see Methods).
Restoration of OX2R in the DR (Ox1r–/–Ox2r–/–+DR-OX2R 
mice) completely prevented cataplexy-like episodes, while the 
fragmentation of wakefulness was unaffected (Figure 2, A and C). 
Excessive REM sleep time was partially but significantly amelio-
rated, while REM sleep latency was not significantly increased, 
in Ox1r–/–Ox2r–/–+DR-OX2R versus control Ox1r–/–Ox2r–/– mice 
(Figure 2B). The mean duration and number of wakefulness epi-
sodes, as well as the total wakefulness time, did not significantly 
differ between groups (Figure 2C and Supplemental Figure 2B).
In clear contrast to the DR, restoration of OX1R in the LC 
(Ox1r–/–Ox2r–/–+LC-OX1R mice) significantly improved the 
maintenance of wakefulness and NREM sleep (Figure 2C and 
Supplemental Figure 2A). Wakefulness episode duration was 
significantly increased and the number of wakefulness episodes 
significantly reduced in Ox1r–/–Ox2r–/–+LC-OX1R versus control 
Ox1r–/–Ox2r–/– mice (Figure 2C). The total time of wakefulness 
was not significantly different between groups (Supplemental 
Figure 2B). However, Ox1r–/–Ox2r–/–+LC-OX1R mice did not 
exhibit a significant change in the frequency of cataplexy-like 
episodes and excess REM sleep time, while it partially but signifi-
cantly ameliorated shortened REM sleep latency, compared with 
Ox1r–/–Ox2r–/– controls (Figure 2, A and B). Targeted restoration 
of OX1R in the PPT or OX2R in the TMN of Ox1r–/–Ox2r–/– mice 
(Ox1r–/–Ox2r–/–+PPT-OX1R and Ox1r–/–Ox2r–/–+TMN-OX2R, 
respectively) did not ameliorate either the fragmentation of 
wakefulness or cataplexy-like episodes (Figure 2).
As described above, orexin receptor expression was driven by the 
ubiquitous EF1α promoter, resulting in their additional expression 
in the vicinity of the DR or LC (Figure 1). In addition, multiple 
types of neurons endogenously express OX1R and/or OX2R in 
these nuclei in WT mice (18). Indeed, only 62.2% ± 2.8% of EGFP+ 
neurons were TPH+ in Ox1r–/–Ox2r–/–+DR-OX2R mice (n = 7), while 
51.2% ± 4.3% of EGFP+ neurons were TH+ in Ox1r–/–Ox2r–/–+LC-OX1R 
mice (n = 7). We next performed Pearson correlation analysis in 
order to examine which neuronal population has a linear dose-
response relationship between the magnitude of amelioration of 
narcoleptic symptoms and the number of cells with restoration of 
orexin receptor expression (Figure 3). For this purpose, we included 
EEG/EMG and histological data of mice with off-target restoration 
(i.e., restoration by orexin receptor in DR serotonergic neurons or 
in LC noradrenergic neurons, which were found to be less than 50% 
and eliminated from the initial analyses). As shown in Figure 3A, 
inhibition of cataplexy-like episodes was highly correlated with the 
number of EGFP+TPH+ cells in the DR, but was not significantly 
correlated with the number of EGFP+TPH– cells within the DR, 
in the region lateral to the DR, or in the ventrolateral part of the 
periaqueductal gray matter (vlPAG), which has previously been 
reported to suppress REM sleep (20). Similarly, the duration of 
wakefulness episodes was highly correlated with the number of 
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EGFP+TH+ cells in the LC, but was not significantly correlated 
with EGFP+TH– cell number within the LC or in any surrounding 
area, such as the subcoeruleus (SubC) region or the parabrachial 
nucleus (PB) (Figure 3B). Taken together, these results suggest that 
restoration of orexin signaling in the DR and in the LC may inhibit 
cataplexy-like episodes and fragmentation of wakefulness, likely 
mediated by serotonergic and noradrenergic neurons, respectively.
Restoration of orexin receptors in DR or LC using neuron type–selective 
promoters. We next aimed to restore the expression of orexin recep-
tors in a neuronal type–selective manner in these areas. In the 
Figure 1
Region-specific restoration of orexin receptor expression in Ox1r–/–Ox2r–/– mice. Coronal brain sections prepared from Ox1r–/–Ox2r–/– mice with targeted 
injection of AAV-EF1α/OX1R::EGFP (B and D) or AAV-EF1α/OX2R::EGFP (A and C) were double-stained with anti-GFP (red) and the neuronal 
type–specific marker (green) antibodies TPH (A), TH (B), HDC (C), and ChAT (D). Regions denoted by white arrowheads are shown at higher magni-
fication. Schematics show the spread of OX1R::EGFP or OX2R::EGFP expression. Mean numbers of EGFP+ cells are shown by green or red circles, 
indicative of the absence or presence, respectively, of the neuronal type–specific marker. For bilaterally injected areas, only 1 side was shown. 3v, third 
ventricle; 4v, fourth ventricle, Aq, aqueduct; SNR, substantia nigra pars reticulata; VMH, ventromedial hypothalamus. Scale bars: 100 μm.
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DR, serotonergic neurons express both OX1R and OX2R (18). 
To selectively target the expression of OX2R in serotonergic neu-
rons, we generated AAV-Pet1/OX2R::EYFP, an AAV vector encod-
ing OX2R::EYFP driven by a 1.8-kb promoter of the Pet1 gene 
(21), which encodes a serotonergic-specific transcription factor. 
When AAV-Pet1/OX2R::EYFP was microinjected into the DR 
(Ox1r–/–Ox2r–/–+5HT-OX2R mice; n = 6), 88.9% ± 2.5% of neurons 
expressing OX2R::EYFP in the DR were also TPH+, whereas 11.1% 
± 2.5% were TPH–, non-serotonergic neurons (Figure 4A). 
Thus, selectivity of OX2R expression in serotonergic neu-
rons was substantially higher in Ox1r–/–Ox2r–/–+5HT-OX2R 
than Ox1r–/–Ox2r–/–+DR-OX2R mice (in which 62.2% ± 2.8% 
of EGFP+ neurons were also TPH+). The proportion 
of DR serotonergic neurons expressing OX2R::EYFP 
was comparable in Ox1r–/–Ox2r–/–+5HT-OX2R and 
Ox1r–/–Ox2r–/–+DR-OX2R mice (75.1% ± 2.2% and 72.0% ± 3.2% 
of EYFP+ neurons, respectively, were also TPH+).
The vlPAG and the lateral pontine tegmentum (LPT)/
deep mesencephalic reticular nucleus (DPMe), located 
adjacent to the DR, inhibit REM sleep (20, 22, 23). How-
ever, few cells in these regions expressed OX2R::EYFP in 
Ox1r–/–Ox2r–/–+5HT-OX2R mice (Figure 4B). Furthermore, 
wake-active dopaminergic neurons in the ventral part of 
the periaqueductal gray matter (vPAG) and a part of the 
adjacent DR have been implicated in promoting wakeful-
ness (24). Nevertheless, we detected OX2R::EYFP in a very 
small population of those TH+ dopaminergic neurons of 
Ox1r–/–Ox2r–/–+5HT-OX2R mice: 1.3% ± 0.5% of EYFP+ 
neurons were also TH+ (3.7 ± 1.1 cells; Figure 4C). It is 
therefore unlikely that the effects of OX2R restoration in 
Ox1r–/–Ox2r–/–+5HT-OX2R mice are mediated by expres-
sion leaked in vlPAG/LPT or vPAG dopaminergic neurons.
The relatively serotonergic-selective OX2R restoration in 
Ox1r–/–Ox2r–/–+5HT-OX2R mice mimicked the effects of non-
selective restoration achieved in Ox1r–/–Ox2r–/–+DR-OX2R 
mice (Figure 5 and Supplemental Figure 3). Suppres-
sion of cataplexy-like episodes was nearly complete in 
Ox1r–/–Ox2r–/–+5HT-OX2R versus control Ox1r–/–Ox2r–/– mice 
(Figure 5A). However, excessive REM sleep time and shortened 
REM sleep latency were not significantly ameliorated in these 
mice (Figure 5B), which suggests that regulation of cataplexy 
and REM sleep are at least partially different.
In the LC, noradrenergic neurons express OX1R exclu-
sively in WT mice (18). To selectively target OX1R expres-
sion in noradrenergic neurons, we generated an AAV vector 
encoding OX1R::EYFP under the control of the PRSx8 pro-
moter (AAV-PRSx8/OX1R::EYFP; ref. 25). This promoter 
has been used for the same purpose in previous studies 
(26–28) and contains a minimal promoter and 8 copies 
of a promoter sequence from the cis-regulatory region of 
the dopamine β-hydroxylase (DBH) gene that binds the 
Phox2a/b transcription factors. These factors are expressed 
in and critical for noradrenergic neurons, but they are also 
expressed in several populations of non-noradrenergic 
neurons in the brainstem. When AAV-PRSx8/OX1R::EYFP 
was microinjected into the LC (Ox1r–/–Ox2r–/–+NA-OX1R), 
OX1R::EYFP was efficiently expressed in noradrenergic 
neurons of the LC, but additionally expressed in many non-
noradrenergic neurons in the adjacent areas, including the 
SubC region and PB (Figure 4, D–G, and ref. 26). Overall, 
60.1% ± 6.7% of neurons expressing OX1R::EYFP were also TH+ 
(n = 6). The proportion of LC noradrenergic neurons expressing 
OX1R::EYFP was comparable between Ox1r–/–Ox2r–/–+NA-OX1R 
and Ox1r–/–Ox2r–/–+LC-OX1R mice (88.6% ± 2.6% and 83.2% ± 3.7% 
of EYFP+ neurons, respectively, were also TH+).
OX1R restoration in Ox1r–/–Ox2r–/–+NA-OX1R mice mim-
icked the effects of nonselective restoration achieved in 
Ox1r–/–Ox2r–/–+LC-OX1R mice (Figure 5). The duration of wakeful-
Figure 2
Restoration of orexin receptor expression in the DR and LC inhib-
its cataplexy-like episodes and consolidates wakefulness, respec-
tively. Control Ox1r–/–Ox2r–/– (n = 16), Ox1r–/–Ox2r–/–+DR-OX2R (n = 7), 
Ox1r–/–Ox2r–/–+LC-OX1R (n = 8), Ox1r–/–Ox2r–/–+TMN-OX2R (n = 4), 
Ox1r–/–Ox2r–/–+PPT-OX1R (n = 4), and WT (n = 4) mice were recorded. Mean 
values of 3 nights’ recordings are shown. Ox1r–/–Ox2r–/– controls were injected 
with AAV-CAG/EGFP into the DR or LC, AAV-Pet1/ChR2::EYFP into the DR, 
or AAV-PRSx8/ChR2::EYFP into the LC. (A) Number of and time spent in 
cataplexy-like episodes. (B) REM sleep latency and time spent in REM sleep. 
(C) Duration and number of wakefulness episodes during the dark phase. 
*P < 0.05, **P < 0.01 vs. Ox1r–/–Ox2r–/– control; #P < 0.05, ##P < 0.01 vs. WT. 
Values are mean ± SEM.
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ness episodes was significantly increased and the number of wakeful-
ness episodes significantly decreased in Ox1r–/–Ox2r–/–+NA-OX1R 
versus control Ox1r–/–Ox2r–/– mice, but these levels were still sig-
nificantly different from those of WT mice (Figure 5C). Impor-
tantly, these parameters of wakefulness were not significantly 
different from those in Ox2r–/– mice (29), which were intermedi-
ate between the parameters in Ox1r–/–Ox2r–/– controls and WT 
mice, as reported previously (1, 30). In WT mice, most wakeful-
ness occurred in episodes longer than 32 minutes (Figure 5D), 
consistent with a value reported previously (30). In contrast, in 
Ox1r–/–Ox2r–/– controls, most wakefulness occurred in episodes of 
intermediate length, and a marginal proportion of wakefulness 
occurred in long episodes (>32 minutes), confirming the fragmen-
tation of wakefulness in these mice. The proportion of wakeful-
ness that occurred in long episodes in Ox1r–/–Ox2r–/–+NA-OX1R 
mice was intermediate between that of Ox1r–/–Ox2r–/– control and 
WT mice. This parameter was not significantly different from that 
in Ox1r–/–Ox2r–/–+LC-OX1R mice and was almost comparable to 
that in Ox2r–/– mice, but was slightly and significantly reduced. In 
contrast, none of the parameters that reflected dysregulated REM 
sleep were significantly improved in Ox1r–/–Ox2r–/–+NA-OX1R ver-
sus control Ox1r–/–Ox2r–/– mice (Figure 5, A and B).
A s  d e s c r i b e d  a b ove ,  OX 1 R : : E Y F P  e x p r e s s i o n  i n 
Ox1r–/–Ox2r–/–+NA-OX1R mice spread into areas adjacent to 
the LC. To evaluate the contribution of such leaked expres-
sion to the effect on fragmented wakefulness, we scored 
the EEG/EMG data of mice with off-target restoration 
(Ox1r–/–Ox2r–/–+non-NA-OX1R mice), which have similar num-
bers of EYFP+TH– cells, but few EYFP+TH+ cells (Supplemental 
Figure 4A). In addition, as we detected a considerable number 
of EYFP+TH– cells in the PB of Ox1r–/–Ox2r–/–+NA-OX1R mice, 
a region that was recently demonstrated to be critical for corti-
cal arousal (31), we focally injected AAV-EF1α/OX1R::EGFP in 
the PB of Ox1r–/–Ox2r–/– mice (Ox1r–/–Ox2r–/–+PB-OX1R mice) 
and analyzed their EEG/EMG as another control (Supplemen-
tal Figure 4B). Importantly, both Ox1r–/–Ox2r–/–+non-NA-OX1R 
and Ox1r–/–Ox2r–/–+PB-OX1R mice demonstrated fragmented 
wakefulness comparable to that of control Ox1r–/–Ox2r–/– mice 
(Supplemental Figure 4, C–H). Furthermore, wakefulness dura-
tion was strongly correlated with the number of EYFP+TH+ cells 
Figure 3
Suppression of narcoleptic symptoms is correlated with the number of serotonergic or noradrenergic neurons with orexin receptor in the DR or LC. 
(A) Correlation between number of cataplexy-like episodes and number of EGFP+ cells in TPH+ DR, TPH– DR, vlPAG, or the region lateral to the 
DR and MnR (including the paratrochlear nucleus and pontine reticular nucleus) of Ox1r–/–Ox2r–/– +DR-OX2R mice (Successfully targeted) and 
those with off-target restoration (Unsuccessfully targeted). (B) Correlation between wakefulness episode duration and number of EGFP+ cells in 
TH+ LC, TH– LC, or regions lateral (including PB), medial, or ventral (including SubC) to the LC of Ox1r–/–Ox2r–/–+LC-OX1R mice and those with 
off-target restoration. Pearson r, P values, and regression lines are shown.
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in the LC, but not with the number of EYFP+TH– cells in any 
surrounding area (Supplemental Figure 5A). We also considered 
the possibility that restoration of orexin signaling in neurons 
expressing neuropeptide S (NPS) contributes to the consolida-
tion of wakefulness in Ox1r–/–Ox2r–/–+NA-OX1R mice: NPS pro-
motes wakefulness and is expressed in a small cluster of neurons 
localized in close proximity to the LC (32). For this purpose, we 
detected OX1R::EYFP mRNA and NPS mRNA simultaneously 
using double in situ hybridization. In Ox1r–/–Ox2r–/–+NA-OX1R 
mice, 38.8% ± 11.2% of NPS+ cells in this area were also EYFP+. 
However, the number of EYFP+NPS+ cells was small and not sig-
nificantly correlated with the duration of wakefulness episodes 
(Supplemental Figure 5B), which suggests that the contribution 
of NPS neurons is unlikely. Together, these results suggest that 
Figure 4
Restoration of orexin receptors in the DR or LC of Ox1r–/–Ox2r–/– mice using neuron type-selective promoters. (A–C) Coronal brain sections from 
Ox1r–/–Ox2r–/–+5HT-OX2R mice (with targeted injection of AAV-Pet1/OX2R::EYFP) were double-stained with anti-GFP antibody (red) and either 
anti-TPH (A and B) or anti-TH (C, for dopaminergic neurons in the DR) antibody (green). (D–G) Sections from Ox1r–/–Ox2r–/–+NA-OX1R mice 
(with AAV-PRSx8/OX1R::EYFP injection) were double-stained with anti-GFP (red) and anti-TH (green) antibodies. Leaked expression of 
OX1R::EYFP in regions lateral (E, including PB), medial (F), and ventral (G, including SubC) to the LC (D) is shown. Regions denoted by white 
arrowheads are shown at higher magnification. Schematics show the spread of OX1R::EYFP or OX2R::EYFP expression. Mean numbers of 
EGFP+ cells are shown by green or red circles, indicative of the absence or presence, respectively, of the neuronal type–specific marker. For LC, 
only 1 side was shown. LPB, lateral PB; MPB, medial PB. Scale bars: 100 μm.
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the orexinergic regulation of LC noradrenergic neurons may 
markedly consolidate wakefulness, to an extent comparable to 
that in Ox2r–/– mice.
Pharmacogenetic activation of DR serotonergic and LC noradrenergic 
neurons in narcoleptic mice. We next examined whether artificial acti-
vation of DR serotonergic and LC noradrenergic neurons improves 
narcoleptic symptoms in orexin/ataxin-3 mice (4). In these mice, 
orexin neurons degenerate postnatally due to the transgenic 
expression of a truncated Machado-Joseph disease gene product, 
mimicking the pathophysiological condition of human narcolep-
sy. For this purpose, we used designer receptors exclusively activat-
ed by designer drugs (DREADD) technology, in which muscarinic 
receptors are mutated so that their ability to bind natural ligands 
is lost, while nanomolar potency is gained for the otherwise phar-
macologically inert ligand clozapine-N-oxide (CNO) (33, 34). The 
stimulatory DREADD, designated “hM3Dq,” couples through the 
Gq pathway to depolarize neurons. Here, we generated AAV vectors 
encoding hM3Dq under the control of the Pet1 or PRSx8 promoter 
(AAV-Pet1/hM3Dq or AAV-PRSx8/hM3Dq).
When AAV-Pet1/hM3Dq was microinjected into the DR (n = 7), 
hM3Dq mRNA expression was detected in 78.4% ± 1.5% of seroto-
nergic neurons in the DR, and 83.1% ± 1.0% of hM3Dq+ cells were 
also TPH+ (Supplemental Figure 6A). No hM3Dq mRNA expres-
sion was detected in the area surrounding the DR. We adminis-
tered saline or CNO i.p. into orexin/ataxin-3 mice injected with 
AAV-Pet1/hM3Dq in the DR immediately before the start of the 
dark period. Compared with saline administration, CNO substan-
tially reduced the frequency of and time spent in cataplexy-like epi-
sodes during the subsequent 6 hours in the dark period (Figure 6, 
A and B). REM sleep latency was significantly increased by CNO 
administration, whereas fragmentation of wakefulness was not 
improved (Figure 6, C and D).
Similarly, when AAV-PRSx8/hM3Dq was microinjected into 
the LC, hM3Dq mRNA expression was detected in 68.1% ± 3.9% 
of noradrenergic neurons in the LC, and 81.1% ± 1.5% of hM3Dq+ 
cells were also TH+ (Supplemental Figure 6B). In these mice, the 
duration of wakefulness episodes during the subsequent 6 hours 
of the dark period was significantly increased, and the number of 
wakefulness episodes was significantly reduced by CNO versus 
saline treatment (Figure 6, G and H). The total time spent in wake-
fulness during the same period was not significantly increased 
by CNO administration (Supplemental Figure 6B). Accordingly, 
Figure 5
Restoration of orexin receptor expression selectively in DR serotonergic and LC noradrenergic neurons suppresses cataplexy-like episodes and 
ameliorates fragmentation of wakefulness, respectively. (A–C) Control virus–injected Ox1r–/–Ox2r–/– (as in Figure 2; n = 16), Ox1r–/–Ox2r–/–+5HT-OX2R 
(n = 6), Ox1r–/–Ox2r–/–+NA-OX1R (n = 5), Ox2r–/– (n = 5), and WT (n = 4) mice were recorded. Mean values of 3 nights’ recordings are shown. Data 
from Figure 2 are included for comparison. (A) Number of and time spent in cataplexy-like episodes. (B) REM sleep latency and time spent in 
REM sleep. (C) Duration and number of wakefulness episodes during the dark phase. *P < 0.05, **P < 0.01 vs. Ox1r–/–Ox2r–/– control; #P < 0.05, 
##P < 0.01 vs. WT. (D) Time-weighted frequency histograms of wakefulness duration in control Ox1r–/–Ox2r–/– (n = 16), Ox1r–/–Ox2r–/–+LC-OX1R 
(n = 8), Ox1r–/–Ox2r–/–+NA-OX1R (n = 5), Ox2r–/– (n = 5), and WT (n = 4) mice, showing the wakefulness that occurred in episodes of each length 
as a percentage of total wakefulness in the dark phase. **P < 0.001 vs. Ox1r–/–Ox2r–/– control; ##P < 0.001 vs. WT; ++P < 0.001 vs. Ox2r–/–, 2-way 
repeated-measures ANOVA. Values are mean ± SEM. 
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the proportion of wakefulness in long episodes was significantly 
increased in CNO- versus saline-treated mice (Figure 6G). In con-
trast, CNO administration did not significantly affect the frequen-
cy of cataplexy-like episodes (Figure 6, E and F). Importantly, the 
wake-stabilizing effect of CNO was not observed in orexin/ataxin-3 
mice with off-target hM3Dq expression, which have similar num-
bers of hM3Dq-expressing cells in the regions surrounding the LC, 
but almost no such cells in the LC (Supplemental Figure 7, A–D). 
In addition, this effect of CNO was strongly correlated with the 
number of hM3Dq+TH+ cells in the LC noradrenergic neurons, but 
not in any surrounding area (Supplemental Figure 7E).
Thus, these data suggest that pharmacogenetic activation of DR 
serotonergic and LC noradrenergic neurons in narcoleptic mice 
may be sufficient to substantially suppress cataplexy-like episodes 
and consolidate wakefulness, respectively. However, the possibility 
formally remains that a small number of non-serotonergic or non-
noradrenergic neurons in the DR or LC expressing hM3Dq also 
contribute to these effects.
Discussion
Technical considerations. One of the technical limitations of this 
study is that AAV vector–mediated expression of orexin recep-
tors could not completely reproduce the endogenous expression 
patterns and levels driven by the native promoters (i.e., ectopic 
expression and overexpression). We used both ubiquitous and 
neuron type–selective promoters to drive orexin receptor expres-
sion. However, even with selective promoters, we observed consid-
erable leaked expression. To address this problem, we performed a 
series of control injection studies and correlation analyses, which 
led to the same conclusion for multiple promoters of different 
characteristics: suppression of cataplexy-like episodes was corre-
lated with the number of DR serotonergic neurons with OX2R 
restoration, while consolidation of fragmented wakefulness was 
correlated with the number of LC noradrenergic neurons with 
OX1R restoration. However, these results do not completely 
exclude the contributions of non-serotonergic and/or non-nor-
adrenergic neurons around these areas.
Figure 6
Pharmacogenetic activation of DR serotonergic and LC noradrenergic neurons suppresses cataplexy-like episodes and consolidates wakeful-
ness, respectively. orexin/ataxin-3 mice with DR serotonergic neuron–selective (A–D; n = 7) or LC noradrenergic neuron–selective (E–H; n = 8) 
expression of hM3Dq were injected with saline or CNO. Mean values of 3 nights’ recordings are shown. (A and E) Number of and time spent in 
cataplexy-like episodes and REM sleep latency. (B and F) Hourly plots of number and total time of cataplexy-like episodes. (C and G) Duration and 
number of wakefulness episodes within 12 hours after saline or CNO administration at ZT 12 (arrows). (G) Time-weighted frequency histogram of 
wakefulness duration is also shown (P < 0.001, drug effect and interaction of drug and wakefulness duration, 2-way repeated-measures ANOVA). 
(D and H) Hourly plots of wakefulness duration and number within 12 hours after administration at ZT 12 (arrows). *P < 0.05, #P < 0.01, 2-tailed 
Student’s paired t test. Values are mean ± SEM.
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It should be noted that the estimated specificities of Pet1 and 
PRSx8 promoters to serotonergic and noradrenergic neurons, 
respectively, were different between orexin receptor restoration 
experiments and DREADD experiments. This discrepancy seemed 
to result from the difference in the methods used to detect trans-
gene expression. Orexin receptors were expressed as proteins fused 
to EGFP or EYFP, which are very stable, and they were detected 
by anti-GFP antibody with high sensitivity, likely leading to the 
efficient detection of leaked expression at very low levels. In con-
trast, because of the lack of a good antibody, hM3Dq expression 
was detected by in situ hybridization as mRNA, which is generally 
unstable, possibly missing low-level expression.
It is important to note that the orexin receptors in the restored 
cells might be expressed at levels different from those of the native 
receptors in WT mice. Therefore, from the standpoint of both 
patterns and expression levels, the reactivation approach, exem-
plified by Mochizuki et al. (30), combined with transgenic mice 
expressing Cre in cell type–specific manners (e.g., mice express-
ing Cre specifically in DR serotonergic neurons or in LC norad-
renergic neurons) would be the ideal strategy to identify cells of 
physiological relevance in the true sense. Nevertheless, our 
approach seemed practical and still had several advantages, includ-
ing higher throughput and detailed verification of receptor expres-
sion patterns owing to the EGFP and EYFP tags.
We failed to observe any amelioration of narcoleptic symptoms 
when orexin receptors were restored in the TMN, PPT, or PB. How-
ever, this result does not completely rule out the possible roles of 
orexin signaling in these nuclei in the suppression of narcolepsy; 
the possibility remains that more efficient restoration in these 
nuclei, in the number of restored cells, and/or in the expression 
levels within the individual cells would be able to suppress nar-
colepsy. Ectopic expression in the areas surrounding the TMN or 
PPT might also mask the contributions of TMN histaminergic 
and PPT cholinergic neurons. It is also possible that these nuclei 
play important roles as downstream targets of orexin neurons 
in cooperation with other nuclei, as discussed below for TMN 
histaminergic neurons. Similarly, although pharmacogenetic 
activation of PB neurons with leaked expression of hM3Dq did not 
enhance wakefulness in this study (Supplemental Figure 7, A–D), 
this result never denies the previously reported wake-promoting 
role of the PB (31).
Finally, our current study did not cover all populations of neu-
rons implicated in the regulation of wakefulness and muscle tone. 
It thus does not exclude the potential roles in suppressing narco-
leptic symptoms played by neurons that were not tested here. Nev-
ertheless, we considered the nuclei examined in the current study 
to satisfy a set of candidates as the start point by which to dis-
sect downstream targets of orexinergic modulation, according to 
well-characterized interactions between orexin neurons and 
monoaminergic and cholinergic neurons.
Roles of orexin receptor activation of DR serotonergic neurons in the sup-
pression of cataplexy-like episodes. Cataplexy-like episodes occurred 
frequently in Ox1r–/–Ox2r–/– mice, but they rarely occurred 
in Ox2r–/– mice and were absent in Ox1r–/– mice (5, 29, 30), 
which suggests that disruption of both OX1R- and OX2R-medi-
ated pathways is required for frequent cataplexy occurrence 
(Figure 7A). This notion is consistent with our conclusion that 
orexin signaling in DR serotonergic neurons may play a criti-
cal role in the prevention of cataplexy-like episodes, as most DR 
serotonergic neurons express both OX1R and OX2R (18). Both 
receptors couple to the Gq/11 subclass of heterotrimeric G proteins 
and evoke excitatory effects on neurons, suggestive of redundant 
intracellular signaling cascades triggered by OX1R and OX2R 
activation (1). It should be noted that nonselective restoration of 
OX2R in the DR tended to be more effective than serotonergic-
selective restoration. This outcome might stem from the differ-
ence in expression levels of restored OX2R driven by the different 
promoters. An alternative explanation implicates the presumable 
accessory roles of orexin signaling in non-serotonergic neurons of 
the DR (e.g., GABAergic neurons), although the number of non-
serotonergic neurons with OX2R restoration did not correlate 
with the extent of cataplexy-like episode suppression (Figure 3A).
The suppression of cataplexy-like episodes by DR serotonergic 
neurons was surprising, as LC noradrenergic neurons have been 
considered to be a likely candidate to prevent cataplexy, according 
to various pharmacological and electrophysiological studies. For 
example, cataplexy in humans and dogs is strongly suppressed by 
drugs that increase noradrenergic tone and is worsened by drugs 
that block noradrenergic signaling (35, 36). In addition, LC neu-
rons cease firing during cataplexy in dogs (37). However, our 
observations never conflicted with the importance of the norad-
renergic system in the pathophysiology of cataplexy. Rather, our 
results indicated that the activation of LC noradrenergic neurons 
by endogenous orexins is not sufficient to suppress cataplexy 
in narcoleptic mice. This view is consistent with the absence of 
cataplectic attacks in mice lacking OX1R (1, 5), the sole subtype 
expressed in LC noradrenergic neurons (6, 18). It is also likely 
that non-LC noradrenergic neurons play important roles in the 
suppression of cataplexy by pharmacological augmentation of 
systemic noradrenergic tone. This idea is supported by the facts 
that A1, A2, A5, and A7 neurons, rather than those of the LC, have 
been implicated in noradrenergic regulation of REM sleep (22, 38) 
Figure 7
Proposed model for OX1R- and OX2R-mediated pathways in 
suppressing narcoleptic symptoms. (A) Prevention of cataplexy-like 
episodes. (B) Consolidation of wakefulness episodes.
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and that A7 noradrenergic neurons send projections to the ventral 
horn of the spinal cord (26), which may be involved in the regula-
tion of muscle tone. In any case, efficient anticataplectic effects of 
noradrenaline reuptake inhibitors may instead suggest that this 
effect is not dependent on the endogenous orexin system, as orex-
inergic activation of noradrenergic neurons is lacking in human 
narcolepsy patients, in which orexin neurons are degenerated. The 
logic here is analogous to the arousal effects of dopamine uptake 
inhibitors: although stimulants are effective in treating the sleepi-
ness of narcolepsy by augmenting mesolimbic dopaminergic tone 
(35, 39), few researchers think that orexin neurons consolidate 
wakefulness mainly by activating dopaminergic neurons. Indeed, 
restoration of orexin signaling in the ventral tegmental area did 
not ameliorate the fragmentation of wakefulness in Ox1r–/–Ox2r–/– 
mice (E. Hasegawa and M. Mieda, unpublished observations).
In contrast to LC noradrenergic neurons, DR serotonergic neu-
rons do not completely cease discharging, but they greatly reduce 
firing rates, to an extent similar to those during NREM sleep (REM 
sleep–off serotonergic neurons) or REM sleep (REM sleep–reduced 
serotonergic neurons) in dogs (40). Thus, although changes in the 
discharge of LC noradrenergic neurons are more closely correlated 
with cataplexy than changes in DR serotonergic neuron discharge, 
these observations by themselves are not conclusive to demonstrate 
a causal relationship between firing rate and cataplexy occurrence. 
Suppression of DR serotonergic neurons by the focal application 
of a 5-HT1A agonist was previously reported to induce cataplexy-
like episodes in cats, with no significant effect on REM sleep (41). 
Even if a reduction of DR serotonergic activity does not directly 
trigger cataplexy, the orexinergic activation of DR serotonergic 
neurons may prevent the permissive condition under which cata-
plexy can be induced by stimuli such as strong emotions. In this 
context, it is intriguing that we observed intense projections of DR 
serotonergic neurons to the amygdala (Supplemental Figure 8). 
Indeed, the amygdala contains cataplexy-related neurons (42), as 
well as REM-active neurons that are inhibited by DR stimulation 
(43). Thus, noradrenergic and DR serotonergic neurons may be 
involved in suppressing cataplexy at different levels.
Intriguingly, other aspects of REM sleep dysregulation in 
Ox1r–/–Ox2r–/– mice were not improved by DR serotonergic 
neuron–selective OX2R restoration, such as shortened REM sleep 
latency and excessive REM sleep time (1, 5). This outcome may reflect 
that REM sleep and cataplexy are regulated by at least partially dis-
tinct mechanisms, as suggested by previous reports and the fact 
that human narcolepsy patients usually remain conscious during 
cataplectic attacks (2, 41, 44–46). Consistent with this view, DR sero-
tonergic neurons do not cease firing during REM sleep without ato-
nia after bilateral lesion of the mediodorsal pons (47), and they dis-
play suppression of spontaneous discharges during the atonic waking 
state induced by carbachol microinjection (48), which suggests that 
suppression of DR serotonergic neurons is correlated with REM 
atonia, rather than with REM sleep per se.
Roles of orexin receptor activation of LC noradrenergic neurons in the 
consolidation of wakefulness. Whereas Ox1r–/– mice show almost nor-
mal sleep/wakefulness states (5), Ox2r–/– mice exhibit sleep/wake 
fragmentation (29). However, this fragmentation was less severe 
than that of orexin–/– mice and Ox1r–/–Ox2r–/– mice on the same 
C57BL/6J genetic background (Figure 5 and refs. 1, 30), which 
suggests that OX1R plays an important role in the maintenance 
of wakefulness in the absence of OX2R (18). Taken in conjunc-
tion with the prior report that LC noradrenergic neurons exclu-
sively express OX1R in WT mice (18), our observations suggest 
that these neurons are responsible for the contribution of OX1R 
to the maintenance of wakefulness, while another OX2R-mediated 
mechanism is further required for the normal regulation of wake-
fulness duration (Figure 7B).
Although LC neurons are basically wake-on neurons, the role 
of LC noradrenergic neurons in arousal remained controversial. 
The view against their wake-promoting role was largely based 
on the fact that lesions limited to the LC only exert small effects 
on the amount of wakefulness (49). However, Dbh–/– mice, which 
lack endogenous noradrenaline, have been reported to exhibit 
reduced wakefulness as well as REM sleep (50). In addition, the 
LC-noradrenaline system was previously shown to be critical in 
maintaining the increased membrane potential of cortical neurons 
in wakeful versus sleep states (51). Moreover, recent optogenetic 
studies demonstrated a causal relationship between the firing of LC 
noradrenergic neurons and transitions from sleep to wakefulness 
(52) and further showed that inhibition of these neurons blocked 
the arousal effects of orexin neuron stimulation (53). These reports 
strongly support our conclusion about the role of the orexinergic 
regulation of LC noradrenergic neurons in the consolidation of 
wakefulness. A caveat to this view is that Ox1r–/– mice do not show 
any overt abnormality of sleep/wakefulness (1, 5). This discrepancy 
may be explained by the redundancy of networks comprising the 
arousal system and/or the rapid compensation of dysfunction 
of LC noradrenergic neurons, as lesions of the LC acutely reduce 
wakefulness for a few days, although the reduction dissipates rap-
idly with time (54–56). The presumptive compensation of OX1R 
deficiency in Ox1r–/– mice is further supported by the finding that 
acute pharmacological blockade of OX1R increases NREM sleep 
in rats (57). Thus, our strategy of focal orexin receptor restoration 
in Ox1r–/–Ox2r–/– mice provided important information that the 
lesion studies may not be able to demonstrate. However, rescue 
experiments may tend to overestimate the role of the restored com-
ponent, owing to the lack of other redundant components. There-
fore, our present results should be carefully interpreted in conjunc-
tion with those obtained using other approaches.
Mochizuki et al. previously reported that focal restoration of 
OX2R in neurons of the posterior hypothalamus, including the 
TMN, reversed the fragmentation of wakefulness in Ox2r-null 
Ox2rTD mice, in which a loxP-flanked transcription disrupter (TD) 
gene cassette prevents the expression of functional OX2R (30). 
In contrast, we failed to observe any improvement of fragmented 
wakefulness in Ox1r–/–Ox2r–/– mice when OX2R expression was 
restored in the TMN and adjacent parts of the posterior hypothala-
mus. OX2R expression in the TMN may be sufficient to consolidate 
wakefulness only in the presence of OX1R expression, presumably 
in the LC (Figure 7B). Thus, OX2R receptors in histamine neurons 
are likely to be physiologically vital when OX1R levels are normal.
Does the neural circuit underlying narcolepsy differ between mice and 
dogs? At least 2 phenotypic forms of narcolepsy have been reported 
in canines. Familial narcolepsy has been maintained in lines of 
Doberman pinschers and Labrador retrievers and is now under-
stood to be due to null mutations of the OX2R gene, whereas 
sporadic nonfamilial narcolepsy is caused by deficiency of orexin 
peptides, like the majority of narcoleptic humans, and has been 
studied to a lesser extent in poodles, beagles, and other small 
breeds (58, 59). As the familial form of canine narcolepsy exhibits 
sleepiness and frequent cataplexy, OX1R has been considered to 
be dispensable for the underlying neural circuit pathophysiology 
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(residues –1,675 to +110, with +1 the transcription initiation site; NCBI 
accession no. NT_039170) was amplified by PCR from genomic DNA of 
C57BL/6J. The HA-tagged hM3Dq cDNA was excised from the plasmid 
pcDNA5/FRT-HA-hM3Dq (33, 34), provided by B.L. Roth (University of 
North Carolina, Chapel Hill, North Carolina, USA). AAV-2 vectors with a 
mutant form of the cap gene, provided by A. Srivastava (University of Florida, 
Gainesville, Florida, USA; ref. 62), were produced using a triple-transfection, 
helper-free method and purified as described previously (63). The titers of 
recombinant AAV vectors were as follows: AAV-EF1α/OX1R::EGFP, 1.5 × 1012 
genome copies/ml; AAV-EF1α/OX2R::EGFP, 1.7 × 1012 genome copies/ml; 
AAV-CAG/EGFP, 3.2 × 1012 genome copies/ml; AAV-PRSx8/OX1R::EYFP, 
8.4 × 1011 genome copies/ml; AAV-Pet1/OX2R::EYFP, 4.2 × 1011 genome 
copies/ml; AAV-PRSx8/ChR2::EYFP, 5.0 × 1012 genome copies/ml; AAV-Pet1/
ChR2::EYFP, 1.3 × 1012 genome copies/ml; AAV-PRSx8/hM3Dq, 7.8 × 1011 
genome copies/ml; AAV-Pet1/hM3Dq, 1.1 × 1012 genome copies/ml.
Surgery. Implantation of an EEG/EMG electrode and stereotaxic injec-
tion of AAV vectors were performed as described previously (63); 0.5–1.0 μl 
purified virus was delivered to each site (0.05 μl/min). After 5 minutes of 
rest, the needles were removed. The stereotaxic coordinates of the Hamilton 
needle syringe placement were as follows: LC (AP, 5.4 mm; ML, ± 0.9 mm 
bilaterally; DV, 3.7 mm); DR (AP, 4.4 mm; ML, ± 0 mm; DV, 3.0 and 3.5 mm); 
TMN (AP, 2.5 mm; ML, ± 1.0 mm bilaterally; DV, 5.6 mm); PPT (AP, 4.5 mm; 
ML, ± 1.0 mm bilaterally; DV, 3.7 mm); PB (AP, –5.4 mm; ML, ± 1.0 mm 
bilaterally; DV, 3.5 mm). After surgery, all animals were housed individually 
for a recovery period of at least 14 days.
Sleep recordings. After the recovery period, EEG/EMG recordings were 
performed on 3 consecutive days, and EEG/EMG data were analyzed as 
previously described (63).
For some mice, we simultaneously videotaped the animals during the 
EEG/EMG recordings and scored cataplexy according to the criteria of 
Scammell et al. (19). As episodes identified as direct transitions from wake-
fulness to REM sleep on the EEG/EMG data perfectly correlated with epi-
sodes of abrupt immobility in the video data of these pilot recordings (total 
77 episodes in 5 Ox1r–/–Ox2r–/– mice; total 53 episodes in 2 orexin/ataxin-3 
mice) and we needed to analyze many animals, we decided to record only 
the EEG/EMG for the rest of the mice studied. Although we believe that the 
identified episodes were equivalent to murine cataplexy, we carefully called 
the direct transitions from wakefulness to REM sleep cataplexy-like episodes, 
according to Scammell et al. (19).
EEG/EMG signals were scored in wakefulness, NREM sleep, REM sleep, 
or cataplexy-like episodes. REM sleep latency was calculated as the latency 
from the onset of sleep (transition from wakefulness to NREM sleep) to 
the first episode of REM sleep within that particular sleep episode. Sleep 
episodes without REM sleep were not included in the calculation of REM 
sleep latency.
Drugs and administration. CNO (C0832, Sigma-Aldrich) was dissolved in 
saline to a concentration of 0.5 mg/ml. CNO or saline was administered 
by i.p. injection to each mouse (0.3 ml/30 g body weight) at Zeitgeber 
time (ZT) 12. Each mouse received 3 saline and 3 CNO administrations 
in an alternating manner, at intervals of 1 day after saline administration 
or 2 days after CNO administration.
Histological study. Double immunostaining was performed as previously 
described (64). Serial coronal brain sections (30 μm thick) were collected 
in 4 series, 1 of which was further immunostained. EGFP/EYFP fluores-
cence was completely quenched before immunostaining by treating sec-
tions with 0.3% hydrogen peroxide. Antibodies used were as follows: goat 
anti-GFP (1:1,000; provided by M. Watanabe, Hokkaido University, Sap-
poro, Hokkaido, Japan); rabbit anti-TH (1:1,000; Chemicon); mouse anti-
TPH (1:200; Sigma-Aldrich); guinea pig anti-HDC (1:4,000; Biotechnik); 
goat anti-ChAT (1:2,000; Millipore); Alexa Fluor 488–conjugated donkey 
of canine narcolepsy, apparently contradicting the results of our 
studies in mice. Thus, it is tempting to speculate a species differ-
ence with respect to orexin receptor expression, for example, that 
OX2R is the predominant subtype in the DR serotonergic neu-
rons of dogs. Alternatively, the possibility remains that the neural 
mechanisms preventing narcolepsy are similar between dogs and 
mice, which depend on both OX1R and OX2R, as suggested by our 
present findings. The familial form of canine narcolepsy has been 
reported to be 30- to 80-fold less severely affected with cataplexy 
compared with the sporadic form (60). Unfortunately, no direct 
experimental comparison of sleepiness between the 2 canine mod-
els has been reported. The difference in genetic background and 
the limited availability of sporadically narcoleptic dogs make it 
difficult to precisely compare the severity of narcoleptic symptoms 
between familial (OX2R-deficient) and sporadic (orexin ligand–
deficient) canine narcolepsy. This drawback of canine studies may 
emphasize the importance of the use of mice in the current study, 
for which a larger number of animals with a uniform genetic back-
ground was available.
Conclusions. Here, we identified 2 critical efferent pathways of 
orexin neurons, which are most likely mediated by DR serotonergic 
and LC noradrenergic neurons differentially regulating cataplexy-
like episode prevention and wakefulness maintenance, respectively. 
Notably, complex neural circuits of the brainstem/hypothalamic 
glutamatergic and GABAergic neurons that generate/suppress 
wakefulness, NREM sleep, or REM sleep have recently emerged 
(20, 22, 23, 31, 61). Orexin neurons, as well as monoaminergic 
and cholinergic neurons in the brainstem and hypothalamus, are 
likely to modulate those glutamatergic- and GABAergic-executing 
circuits of cortical activation and muscle atonia. Therefore, our 
findings provide new insight into not only the pathophysiology 
of narcolepsy, but also the mechanisms of the orexin system as a 
wakefulness stabilizer in normal sleep/wakefulness.
Finally, our success in improving narcoleptic symptoms by DRE-
ADD may lead to a novel type of gene therapy: an artificial recep-
tor-ligand system (with well-established effectiveness, specificity, 
and safety) in which an artificial receptor can be delivered into 
neurons using a viral vector in order to ameliorate symptoms of 
interest, together with subsequent administration of an artificial 
ligand for the receptor with the appropriate timing.
Methods
Animals. 12- to 20-week-old male mice (Ox1r–/–Ox2r–/– and Ox2r–/–, N7 
backcrossed to C57BL/6J, generated by crosses between homozygous 
mice; orexin/ataxin-3, N>7 backcrossed to C57BL/6J; and WT C57BL/6J) 
were used (1, 4, 29). Mice were maintained under a strict 12-hour 
light/12-hour dark cycle in a temperature- and humidity-controlled 
room and fed ad libitum.
Construction of recombinant AAV vectors. The common structure of the 
AAV-2 ITR-containing plasmids used in this study is ITR–promoter–
cDNA encoding a protein–WPRE–poly A signal–ITR. cDNAs encod-
ing rat OX1R or OX2R tagged with EGFP or EYFP at the C terminus 
were used. The EF1α promoter and ChR2-EYFP cDNA were derived from 
pAAV-DIO-hChR2(H134R)-EYFP-WPRE-pA, provided by K. Deisseroth (Stan-
ford University, Stanford, California, USA). The CAG promoter was derived 
from pAAV-FLEX-rev-ChR2mCherry, provided by S.M. Sternson (Janelia Farm 
Research Campus, Ashbum, Virginia, USA). The PRSx8 promoter frag-
ment was provided by K.-S. Kim (Harvard Medical School, Belmont, Mas-
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Supplemental Figure 1. Projections of orexin neurons are preserved in OX1R-/-;OX2R-/- 
mice. Coronal brain sections prepared from OX1R-/-;OX2R-/- and wild-type mice were 
stained brown with anti-orexin A antibody and counterstained with hematoxylin. 
Orexin-immunoreactive nerve fibers are indicated by arrowheads. The locations of the 
magnified images are indicated by boxes in the low-power images. Scale bars, 100 µm. 
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Supplemental Figure 2. Region-specific restoration of orexin receptor expression in 
OX1R-/-;OX2R-/- mice. (A) Mean duration and number of NREM sleep episodes. (B) Total 
time spent in wakefulness and NREM sleep during the dark phase in OX1R-/-;OX2R-/- mice 
with or without the targeted restoration of orexin receptor expression in the indicated nuclei  
(and the subtype of orexin receptor) and wild-type (WT) mice in the dark phase. Mean 
values of three nights’ recordings are shown. Control (1R-/-;2R-/-) was OX1R-/-;OX2R-/- mice 
with AAV-CAG/EGFP injection into the DR or LC, AAV-Pet1/ChR2::EYFP in DR, or 
AAV-PRSx8/ChR2::EYFP in LC. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 
vs. wild-type mice. Values are mean ± S.E. (n = 16 for control, n = 7 for DR-restored, n = 8 
for LC-restored, n = 4 for TMN-restored, n = 4 for PPT-restored, n = 5 for PPT-restored, n 
= 4 for wild-type mice). 




Supplemental Figure 3. Neuronal type-selective restoration of orexin receptor expression 
in the DR and LC of OX1R-/-;OX2R-/- mice. (A) Mean duration and number of NREM sleep 
episodes. (B) Total time spent in wakefulness and in NREM sleep during the dark phase in 
OX1R-/-;OX2R-/- mice with control virus injection (1R-/-;2R-/-: same as in Supplemental 
Figure 2), those with neuron type-selective restoration of orexin receptor expression 
(DR-5HT-2: DR serotonergic-selective OX2R restoration = OX1R-/-;OX2R-/-+5HT-OX2R 
mice; LC-NA-1: LC noradrenergic-selective OX1R restoration = 
OX1R-/-;OX2R-/-+NA-OX1R mice), OX2R-/-, and wild-type mice (data from the 
Supplemental Figure 2 are included for comparison) in the dark phase. Mean values of 
three nights’ recordings are shown. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 
0.01 vs. wild-type mice. 
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Supplemental Figure 4. The restoration of orexin receptor expression in the regions 
surrounding the LC does not ameliorate narcoleptic symptoms. (A, B) Expression of 
OX1R::EYFP (A) or OX1R::EGFP (B) in OX1R-/-;OX2R-/-+non-NA-OX1R mice (A), which 
have similar numbers of EYFP(+)/TH(-) cells but have few EYFP(+)/TH(+) cells as 
Hasegawa et al. – Supplemental Page 5 
 
compared to OX1R-/-;OX2R-/-+NA-OX1R mice, and in OX1R-/-;OX2R-/-+PB-OX1R mice (B), 
which received the focal injection of AAV-EF1α/OX1R::EGFP in their PB. (C-H) 
Sleep/wakefulness parameters of OX1R-/-;OX2R-/-+non-NA-OX1R and 
OX1R-/-;OX2R-/-+PB-OX1R mice during the dark phase. (C) Number of and time spent in 
cataplexy-like episodes. (D) Mean REM sleep latency and time spent in REM sleep. (E) 
Mean duration and number of wakefulness episodes. (F) Mean duration and number of 
NREM sleep episodes. (G) Time spent in wakefulness and NREM sleep. *P < 0.05, **P < 
0.01 vs. control; #P < 0.05, ##P < 0.01 vs. wild-type mice. (H) Time-weighted frequency 
histograms of wakefulness duration showing the proportion of wakefulness that occurred in 
episodes of each length to the total amount of wakefulness in the dark phase. 1R-/-;2R-/-, 
control mice as in Supplemental Figure 2 (n = 16); LC-1, OX1R-/-;OX2R-/-+LC-OX1R mice 
(n = 8); PB-1, OX1R-/-;OX2R-/-+PB-OX1R mice (n = 6); LC-NA-1, 
OX1R-/-;OX2R-/-+NA-OX1R mice (n = 5); non-NA-1, OX1R-/-;OX2R-/-+non-NA-OX1R mice 
(n = 6); WT, wild-type mice  (n = 4).  
  




Supplemental Figure 5. Consolidation of fragmented wakefulness is correlated with the 
number of noradrenergic neurons restored with OX1R in the LC. (A) Correlation between 
the mean duration of wakefulness episodes and the number of EYFP(+) cells in the LC 
noradrenergic neurons, or in the region lateral (including parabrachial nucleus: PB), medial, 
or ventral (including subcoeruleus region: SubC) to the LC of OX1R-/-;OX2R-/-+NA-OX1R 
mice and OX1R-/-;OX2R-/-+non-NA-OX1R mice. Pearson’s correlation coefficients (r), P 
values, and regression lines are also shown. (B) Expression of OX1R::EYFP (orange stain) 
and NPS mRNA (blue stain) around the LC of OX1R-/-;OX2R-/-+NA-OX1R mice and 
OX1R-/-;OX2R-/-+non-NA-OX1R mice, and correlation between the mean duration of 
wakefulness episodes and the number of EYFP(+);NPS(+) cells in these mice. 
Representative EYFP(+);NPS(-), EYFP(-);NPS(+), and EYFP(+);NPS(+) cells are indicated 
by red, blue, and green arrowheads, respectively. 
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Supplemental Figure 6. Pharmacogenetic activations of LC noradrenergic and DR 
serotonergic neurons in orexin/ataxin-3 mice. Expression of hM3Dq and sleep parameters 
after the injection of CNO or saline in orexin/ataxin-3 mice with DR serotonergic (A) or 
LC noradrenergic (B) neuron-selective expression of hM3Dq. For expression analyses, 
coronal brain sections containing the DR or LC were initially hybridized in situ to an 
hM3Dq antisense probe (red), then were immunostained with anti-TPH or anti-TH 
antibodies. The locations of the magnified images are indicated by white arrowheads in the 
low-power images (green). The intense red staining indicated by an arrow (B) was likely to 
be non-specific, because similar staining was observed also in sections of mice that had not 
received AAV injections. Total time spent in REM sleep, wakefulness, and in NREM sleep, 
mean duration and number of NREM sleep episodes within 6 h after saline or CNO 
administration at ZT12 are shown. *P < 0.05, **P < 0.01; two-tailed Student’s paired t test. 
Values are mean ± S.E. (n = 7 for DR, n = 8 for LC).  
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Supplemental Figure 7. Consolidation of fragmented wakefulness by CNO administration 
is correlated with the number of hM3Dq-expressing cells in the LC noradrenergic neurons. 
(A) The wake-stabilizing effect of CNO was not observed in orexin/ataxin-3 mice with 
off-target hM3Dq expression, which have similar numbers of hM3Dq-expressing cells in 
the regions surrounding the LC but have almost no such cells in the LC. Expression of 
hM3Dq mRNA (A), time spent in, mean duration and number of each stage within 6 h after 
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saline or CNO administration at ZT12 are shown (B), as well as hourly plots of mean 
wakefulness duration and number after administrations (C) and time-weighted frequency 
histogram of wakefulness duration (D) within 6 h after saline or CNO administration at 
ZT12. *P < 0.05, **P < 0.01; two-tailed Student’s paired t test. Values are mean ± S.E. (n 
= 10). The intense red staining indicated by an arrow was likely to be non-specific, because 
similar staining was observed also in sections of mice that had not received AAV injections. 
(E) Correlation between the mean duration of wakefulness episodes within 6 h after CNO 
administration and the number of hM3Dq(+) cells in the LC TH(+) neurons, LC TH(-) 
neurons, or in the region lateral (including PB) or medial to the LC of orexin/ataxin-3 mice 
with LC noradrenergic neuron-selective (Successfully targeted) or off-target 
(Unsuccessfully targeted) hM3Dq expression. hM3Dq(+) cells were not detected in the 
SubC area. Pearson’s correlation coefficients (r), P values, and regression lines are also 
shown.  





Supplemental Figure 8. DR serotonergic neurons innervate the nuclei involved in the 
regulation of sleep/wakefulness and emotion. Coronal brain sections prepared from 
OX1R-/-;OX2R-/- mice with the targeted injection of AAV-Pet1/ChR2::EYFP in the DR, 
which were analyzed as a part of control mice for orexin receptor restoration experiments, 
were stained brown with anti-GFP antibody or double-stained with anti-GFP antibody (red 
fluorescence) and one of the antibodies for neuronal type-specific markers (green 
fluorescence): TH for dopaminergic neurons of substantia nigra compacta (SNc), TPH for 
DR serotonergic neurons, and ChAT for cholinergic neurons of LDT. EYFP-positive fibers 
were observed in many areas, with particularly dense innervations to the central and 
basolateral nuclei of the amygdala, SNc, and PPT/LDT. The PPT/LDT contains 
REM-active cholinergic neurons implicated in the initiation of REM sleep and REM atonia. 
Cataplexy is often triggered by strong emotions, which are controlled by the amygdala. 
Thus, DR serotonergic neurons may coordinately control multiple brain regions involved in 
the regulation of REM sleep and emotion under the control of orexin neurons, to prevent 
cataplexy-like episodes. The locations of magnified images are indicated by arrowheads in 
the low-power images. 4v, fourth ventricle; Aq, aqueduct; opt, optic tract. Scale bars, 100 
µm. 
